Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

Leukemia Research

Volumn 33, Issue 8, 2009, Pages 1079-1081

  Guastafierro, Salvatore ^a   Falcone, Umberto ^a   Celentano, Maria ^a   Coppola, Milena ^a   Ferrara, Maria Giovanna ^a   Sica, Antonello ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

CML; Combination therapy; Imatinib mesylate discontinuation

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HYDROXYUREA; IMATINIB; LACTATE DEHYDROGENASE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRANULOPOIESIS; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE DIFFERENTIAL COUNT; LEUKOCYTOSIS; MALE; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; RNA, MESSENGER; RNA, NEOPLASM; TIME FACTORS;

EID: 67349120559     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.11.027     Document Type: Article

References (21)

1. Goldman J.M. How I treat chronic myeloid leukaemia in the imatinib era. Blood 110 (2007) 2328-2337
2. Kantarjian H., Talpaz M., O'Brien S., Garcia-Manero G., Verstovsek S., Giles F., et al. High dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukaemia. Blood 103 (2004) 2873-2878
3. O'Brien S.G., Guilhot F., Larson R.A., Gathmann I., Baccarani M., Cervantes F., et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 348 (2003) 994-1004
4. Kantarjian H.M., O'Brien S., Cortes J., Giles F.J., Rios M.B., Shan J., et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in the chronic phase: comparison with historic data. Cancer 98 (2003) 2636-2642
5. Roy L., Guilhot J., Krahnke T., Guerci-Bresler A., Druker B.J., Larson R.A., et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 108 (2006) 1478-1484
6. Rousselot P., Huguet F., Rea D., Legros L., Cayuela J.M., Maarek O., et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109 (2007) 58-60
7. Higashi T., Tsukada J., Kato C., Iwashige A., Mizobe T., Machida S., et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 76 (2004) 275-278
8. Okabe S., Tauchi T., Ishii Y., Akahane D., Nunoda K., Honda S., et al. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy. Int J Hematol 85 (2007) 173-174
9. Mauro M.J., Druker B.J., and Maziarz R.T. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28 Suppl. 1 (2004) S71-S73
10. Cortes J., O'Brien S., and Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104 (2004) 2204-2205
11. Ali R., Ozkalemkaş F., Ozçelik T., Ozkocaman V., Ozan U., Kimya Y., et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML) Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 29 (2005) 971-973
12. Merante S., Orlandi E., Bernasconi P., Calatroni S., Boni M., and Lazzarino M. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90 (2005) 979-981
13. Hess G., Bunjes D., Siegert W., Schwerdtfeger R., Ledderose G., Wassmann B., et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 23 (2005) 7583-7593
14. Breccia M., Diverio D., Pane F., Nanni M., Russo E., Biondo F., et al. Discontinuation of imatinib therapy after achievement of complete molecular response in a Ph(+) CML patient treated while in long lasting complete cytogenetic remission (CCR) induced by interferon. Leuk Res 30 (2006) 1577-1579
15. Verma D., Kantarjian H., Jain N., and Cortes J. Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha. Leuk Lymphoma 49 (2008) 1399-1402
16. Mahon F.X., Delbrel X., Cony-Makhoul P., Fabères C., Boiron J.M., Barthe C., et al. Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alpha. J Clin Oncol 20 (2002) 214-220
17. Verbeek W., König H., Boehm J., Kohl D., Lange C., Heuer T., et al. Continuous complete hematological and cytogenetic remission with molecular minimal residual disease 9 years after discontinuation of interferon-alpha in a patient with Philadelphia chromosome-positive chronic myeloid leukaemia. Acta Haematol 115 (2006) 109-112
18. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., et al. Dynamics of chronic myeloid leukaemia. Nature 435 (2005) 1267-1270
19. Wodarz D. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: implications for the outcome of imatinib treatment and discontinuation. Med Hypotheses 70 (2008) 128-136
20. Carella A.M. Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation. Leukemia 22 (2008) 1090-1091
21. Burchert A., Wölfl S., Schmidt M., Brendel C., Denecke B., Cai D., et al. Interferon-α, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101 (2003) 259-264